The report provides a detailed analysis essential for establishing a nebivolol (Bystolic) production plant. It encompasses all critical aspects necessary for nebivolol (Bystolic) production, including the cost of nebivolol (Bystolic) production, nebivolol (Bystolic) plant cost, nebivolol (Bystolic) production costs, and the overall nebivolol (Bystolic) production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a nebivolol (Bystolic) production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Nebivolol (Bystolic) is a generic name for the medication that is widely used in the medical and pharmaceutical industries. It is majorly utilized for the treatment of hypertension or high blood pressure. It is also associated with reducing the risks of heart failure and improving its function. Moreover, it also finds its application as a medicine prescribed for its vasodilating properties to enhance blood flow to the heart and reduce the risk of fatal cardiovascular events in patients with certain heart conditions.
The market for nebivolol (Bystolic) is majorly driven by its broad usage as an anti-hypertensive medication to treat high blood pressure, which remarkably promotes its demand in the pharmaceutical industry. Additionally, its usage for the treatment of heart failure and promoting cardiovascular health further amplifies its demand in the medical and pharmaceutical industries. Furthermore, several factors influence industrial nebivolol (Bystolic) procurement, such as the availability of raw materials (6-Fluoro-4-oxo-4H-1-benzopyran-2-carboxylic acid, etc.), cost and pricing, compliance with medical and pharmaceutical regulations, quality standards, technological advancements, environmental considerations, sustainability practices, distribution (including trading and shipping), logistics, safety standards, etc.
Raw Material for Nebivolol (Bystolic) Production
According to the Nebivolol (Bystolic) production plant project report, the major raw material for Nebivolol (Bystolic) production includes 6-Fluoro-4-oxo-4H-1-benzopyran-2-carboxylic acid.
Production Process of Nebivolol (Bystolic)
The extensive nebivolol (Bystolic) production cost report consists of the following industrial production process:
- Production via Catalytic Hydrogenation: This method of production is initiated by the catalytic hydrogenation of 6-fluoro-4-oxo-4H-1-benzopyran-2-carboxylic acid in the presence of Pd-C catalyst to form 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid. Further, the obtained product is transformed into the corresponding ketone through the coupling reactions of carbonyldiimidazole with acids, followed by its reduction with bis-(2-methylpropyl)-aluminum hydride to give an aldehyde. Then, the obtained aldehyde is reacted with trimethylsulfoxonium iodide to synthesize oxiranyl chromane through the Corey–Chaykovsky reaction. Oxiranyl chromane is then subjected to reflux with benzylamine in ethanol, which facilitates the two ring-opening reactions to form a bis-product, followed by hydrogenation in the presence of a Pd-C catalyst to produce nebivolol as the desired product.
Nebivolol (Bystolic) belongs to the chromanes family and is regarded as a secondary amino molecule, diol, and secondary alcohol. Its molecular formula is C22H25F2NO4, and the molecular weight is 405.4 g/mol. Moreover, the IUPAC name of the compound is 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2 -hydroxyethyl]amino]ethanol. The melting point of this drug is 223.0-228.0 degrees Celsius. It is a racemic combination of (S,R,R,R) and (R,S,S,S) enantiomers. It is regarded as the most potent β1-selective adrenoceptor antagonist that is currently approved for clinical use. This drug may have some side effects, including headache, rash, and sleeplessness.